Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVID-19 Bivalent Protein Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Coviccine® is a recombinant bivalent (XBB+Prototype) protein vaccine (Sf9 Cell) for COVID-19 which is effective against multiple strains, especially with a particularly significant increase in neutralizing antibodies against XBB series variants.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : COVID-19 Bivalent Protein Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable